WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers

TheScientificWorldJournal

Volumn 7, Issue , 2007, Pages 649-665

  Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Elisseeva, Olga A ^a   Nakajima, Hiroko ^a   Fujiki, Fumihiro ^a   Kawakami, Manabu ^a   Shirakata, Toshiaki ^a   Nishida, Sumiyuki ^a   Hosen, Naoki ^a   Oji, Yusuke ^a   Kawase, Ichiro ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer; Clinical trial; Immunotherapy; Vaccine; WT1

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; EPITOPE; GEMCITABINE; GENE PRODUCT; HLA ANTIGEN CLASS 1; IMATINIB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; TUMOR ANTIGEN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BLAST CELL; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLONY FORMING CELL; CYTOTOXIC T LYMPHOCYTE; GENE REARRANGEMENT; GENE TARGETING; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO CULTURE; LEUKEMIA CELL; LEUKOPENIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCYTOPENIA; PERIPHERAL CIRCULATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; TUMOR MODEL; TUMOR REGRESSION; TUMOR REJECTION;

CANCER VACCINES; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; VACCINES, SUBUNIT; WT1 PROTEINS;

MUS;

EID: 34249817898     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2007.119     Document Type: Review

References (84)

1. Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yeger, H., Lewis, W.H., Jones, C., and Housman D.E. (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60, 509-520.
2. Gessler, M., Poustka, A., Cavenee, W., Neve, R.L., Orkin, S.H., and Bruns, G.A. (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774-778.
3. Drummond, I.A., Madden, S.L., Rohwer-Nutter, P., Bell, G.I., Sukhatme, V.P., and Rauscher, F.J., 3rd (1992) Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257, 674-678.
4. Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C., Re, G.G., Garvin, A.J., Rosner, M.R., and Haber, D.A. (1995) WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14, 4662-4675.
5. Goodyer, P., Dehbi, M., Torban, E., Bruening, W., and Pelletier, J. (1995) Repression of the retinoic acid receptoralpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 10, 1125-1129.
6. Hewitt, S.M., Hamada, S., McDonnell, T.J., Rauscher, F.J., 3rd, and Saunders, G.F. (1995) Regulation of the protooncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res. 55, 5386-5389.
7. Kim, J., Prawitt, D., Bardeesy, N., Torban, E., Vicaner, C., Goodyer, P., Zabel, B., and Pelletier, J. (1999) The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol. Cell. Biol. 19, 2289-2299.
8. Miwa, H., Beran, M., and Saunders, G.F. (1992) Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6, 405-409.
9. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffler, H.P., and Miyoshi, I. (1993) Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 7, 970-977.
10. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidate, T., Akiyama, T., and Kishimoto, T. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84, 3071-3079.
11. Brieger, J., Weidmann, E., Fenchel, K., Mitrou, P.S., Hoelzer, D., and Bergmann, L. (1994) The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8, 2138-2143.
12. Menssen, H.D., Renkl, H.J., Rodeck, U., Maurer, J., Notter, M., Schwartz, S., Reinhardt, R., and Thiel, E. (1995) Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9, 1060-1067.
13. Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E., and Hoelzer, D. (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90, 1217-1225.
14. Menssen, H.D., Renkl, H.J., Rodeck, U., Kari, C., Schwartz, S., and Thiel, E. (1997) Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int. J. Cancer 70, 518-523.
15. Tamaki, H., Ogawa, H., Ohyashiki, K., Ohyashiki, J.H., Iwama, H., Inoue, K., Soma, T., Oka, Y., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E.H., Kawakami, M., Fuchigami, K., Tomonaga, M., Toyama, K., Aozasa, K., Kishimoto, T., and Sugiyama, H. (1999) The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13, 393-399.
16. Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E.H., Hosen, N., Murakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Nishida, S., Oji, Y., Oka, Y., and Sugiyama, H. (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101, 1698-1704.
17. Oji, Y., Ogawa, H., Tamaki, H., Oka, Y., Tsuboi, A., Kim, E.H., Soma, T., Tatekawa, T., Kawakami, M., Asada, M., Kishimoto, T., and Sugiyama, H. (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90, 194-204.
18. Oji, Y., Miyoshi, S., Maeda, H., Hayashi, S., Tamaki, H., Nakatsuka, S., Yao, M., Takahashi, E., Nakano, Y., Hirabayashi, H., Shintani, Y., Oka, Y., Tsuboi, A., Hosen, N., Asada, M., Fujioka, T., Murakami, M., Kanato, K., Motomura, M., Kim, E. H., Kawakami, M., Ikegame K., Ogawa, H., Aozasa, K., Kawase, I., and Sugiyama, H. (2002) Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int. J. Cancer 100, 297-303.
19. Miyoshi, Y., Ando, A., Egawa, C., Taguchi, T., Tamaki, Y., Tamaki, H., Sugiyama, H., and Noguchi, S. (2002) High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 8, 1167-1171.
20. Oji, Y., Miyoshi, Y., Koga, S., Nakano, Y., Ando, A., Nakatsuka, S., Ikeba, A., Takahashi, E., Sakaguchi, N., Yokota, A., Hosen, N., Ikegame, K., Kawakami, M., Tsuboi, A., Oka, Y., Ogawa, H., Aozasa, K., Noguchi, S., and Sugiyama, H. (2003) Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci. 94, 606-611.
21. Oji, Y., Yamamoto, H., Nomura, M., Nakano, Y., Ikeba, A., Nakatsuka, S., Abeno, S., Kiyotoh, E., Jomgeow, T., Sekimoto, M., Nezu, R., Yoshikawa, Y., Inoue, Y., Hosen, N., Kawakami, M., Tsuboi, A., Oka, Y., Ogawa, H., Souda, S., Aozasa, K., Monden, M., and Sugiyama, H. (2003) Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 94, 712-717.
22. Oji, Y., Suzuki, T., Nakano, Y., Maruno, M., Nakatsuka, S., Jomgeow, T., Abeno, S., Tatsumi, N., Yokota, A., Aoyagi, S., Nakazawa, T., Ito, K., Kanato, K., Shirakata, T., Nishida, S., Hosen, N., Kawakami, M., Tsuboi, A., Oka, Y., Aozasa, K., Yoshimine, T., and Sugiyama, H. (2004) Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci. 95, 822-827.
23. Nakahara, Y., Okamoto, H., Mineta, T., and Tabuchi, K. (2004) Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol. 21, 113-116.
24. Oji, Y., Yano, M., Nakano, Y., Abeno, S., Nakatsuka, S., Ikeba, A., Yasuda, T., Fujiwara, Y., Takiguchi, S., Yamamoto, H., Fujita, S., Kanato, K., Ito, K., Jomgeow, T., Kawakami, M., Tsuboi, A., Shirakata, T., Nishida, S., Hosen, N., Oka, Y., Aozasa, K., Monden, M., and Sugiyama, H. (2004) Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res. 24, 3103-3108.
25. Oji, Y., Nakamori, S., Fujikawa, M., Nakatsuka, S., Yokota, A., Tatsumi, N., Abeno, S., Ikeba, A., Takashima, S., Tsujie, M., Yamamoto, H., Sakon, M., Nezu, R., Kawano, K., Nishida, S., Ikegame, K., Kawakami, M., Tsuboi, A., Oka, Y., Yoshikawa, K., Aozasa, K., Monden, M., and Sugiyama, H. (2004) Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 95, 583-587.
26. Yamagami, T., Sugiyama, H., Inoue, K., Ogawa, H., Tatekawa, T., Hirata, M., Kudoh, T., Akiyama, T., Murakami, A., and Maekawa, T. (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87, 2878-2884.
27. Inoue, K., Tamaki, H., Ogawa, H., Oka, Y., Soma, T., Tatekawa, T., Oji, Y., Tsuboi, A., Kim, E.H., Kawakami, M., Akiyama, T., Kishimoto, T., and Sugiyama, H. (1998) Wilms' tumor gene (WT1) competes with differentiation- inducing signal in hematopoietic progenitor cells. Blood 91, 2969-2976
28. Tsuboi, A., Oka, Y., Ogawa, H., Elisseeva, O.A., Tamaki, H., Oji, Y., Kim, E.H., Soma, T., Tatekawa, T., Kawakami, M., Kishimoto, T., and Sugiyama, H. (1999) Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk. Res. 23, 499-505.
29. Melief, C.J. and Kast, W.M. (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145, 167-177.
30. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
31. Ritz, J. (1994) Tumor immunity: will new keys unlock the door? J. Clin. Oncol. 12, 237-238.
32. Oka, Y., Elisseeva, O.A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E.H., Soma, T., Asada, M., Ueda, K., Maruya, E., Saji, H., Kishimoto, T., Udaka, K., and Sugiyama, H. (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics 51, 99-107.
33. Oka, Y., Udaka, K., Tsuboi, A., Elisseeva, O.A., Ogawa, H., Aozasa, K., Kishimoto, T., and Sugiyama, H. (2000) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164, 1873-1880.
34. Oka, Y., Tsuboi, A., Elisseeva, O.A., Udaka, K., and Sugiyama, H. (2002) WT1 as a novel target antigen for cancer immunotherapy. Curr. Cancer Drug Targets 2, 45-54.
35. Sugiyama, H. (2002) Cancer immunotherapy targeting WT1 protein. Int. J. Hematol. 76, 127-132.
36. Gao, L., Bellantuono, I., Elsasser, A., Marley, S.B., Gordon, M.Y., Goldman, J.M., and Stauss, H.J. (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203.
37. Ohminami, H., Yasukawa, M., and Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286-293.
38. Makita, M., Hiraki, A., Azuma, T., Tsuboi, A., Oka, Y., Sugiyama, H., Fujita, S., Tanimoto, M., Harada, M., and Yasukawa, M. (2002) Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin. Cancer Res. 8, 2626-2631.
39. Bellantuono, I., Gao, L., Parry, S., Marley, S., Dazzi, F., Apperley, J., Goldman, J.M., and Stauss, H.J. (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100, 3835-3837.
40. Li, Z., Oka, Y., Tsuboi, A., Masuda, T., Tatsumi, N., Kawakami, M., Fujioka, T., Sakaguchi, N., Nakajima, H., Fujiki, F., Udaka, K., Oji, Y., Kawase, I., and Sugiyama, H. (2005) WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies. Int. J. Hematol. 82, 458-459.
41. Azuma, T., Makita, M., Ninomiya, K., Fujita, S., Harada, M., and Yasukawa, M. (2002) Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br. J. Haematol. 116, 601-603.
42. Savage, P., Gao, L., Vento, K., Cowburn, P., Man, S., Steven, N., Ogg, G., McMichael, A., Epenetos, A., Goulmy, E., and Stauss, H.J. (2004) Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103, 4613-4615.
43. Koesters, R., Linnebacher, M., Coy, J.F., Germann, A., Schwitalle, Y., Findeisen, P., and Von Knebel Doeberitz, M. (2004) WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int. J. Cancer 109, 385-392.
44. Moudgil, K. and Sercarz, E. (1994) Can antitumor immune responses discriminate between self and nonself? Immunol. Today 15, 353-355.
45. Ohno, S. (1992) How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level. Proc. Natl. Acad. Sci. U. S. A. 89, 4643-4647.
46. Tsuboi, A., Oka, Y., Udaka, K., Murakami, M., Masuda, T., Nakano, A., Nakajima, H., Yasukawa, M., Hiraki, A., Oji, Y., Kawakami, M., Hosen, N., Fujioka, T., Wu, F., Taniguchi, Y., Nishida, S., Asada, M., Ogawa, H., Kawase, I., and Sugiyama, H. (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol. Immunother. 51, 614-620.
47. Doubrovina, E.S., Doubrovin, M.M., Lee, S., Shieh, J.H., Heller, G., Pamer, E., and O'Reilly, R.J. (2004) In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptidespecific T cells with in vitro and in vivo tumoricidal activity. Clin. Cancer Res. 10, 7207-7219.
48. Gao, L., Xue, S.A., Hasserjian, R., Cotter, F., Kaeda, J., Goldman, J.M., Dazzi, F., and Stauss, H.J. (2003) Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75, 1429-1436.
49. Makita, M., Hiraki, A., Azuma, T., Tsuboi, A., Oka, Y., Sugiyama, H., Fujita, S., Tanimoto, M., Harada, M., and Yasukawa, M. (2002) Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin. Cancer Res. 8, 2626-2631.
50. Gaiger, A., Reese, V., Disis, M.L., and Cheever, M.A. (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96, 1480-1489.
51. Gaiger, A., Carter, L., Greinix, H., Carter, D., McNeill, P.D., Houghton, R.L., Cornellison, C.D., Vedvick, T.S., Skeiky, Y.A., and Cheever, M.A. (2001) WT1-specific serum antibodies in patients with leukemia. Clin. Cancer Res. 7, 761s-765s.
52. Elisseeva, O.A., Oka, Y., Tsuboi, A., Ogata, K., Wu, F., Kim, E.H., Soma, T., Tamaki, H., Kawakami, M., Oji, Y., Hosen, N., Kubota, T., Nakagawa, M., Yamagami, T., Hiraoka, A., Tsukaguchi, M., Udaka, K., Ogawa, H., Kishimoto, T., Nomura, T., and Sugiyama, H. (2002) Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99, 3272-3279.
53. Wu, F., Oka, Y., Tsuboi, A., Elisseeva, O.A., Ogata, K., Nakajima, H., Fujiki, F., Masuda, T., Murakami, M., Yoshihara, S., Ikegame, K., Hosen, N., Kawakami, M., Nakagawa, M., Kubota, T., Soma, T., Yamagami, T., Tsukaguchi, M., Ogawa, H., Oji, Y., Hamaoka, T., Kawase, I., and Sugiyama, H. (2005) Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19, 268-274.
54. Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D., and Keilholz, U. (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100, 2132-2137.
55. Rezvani, K., Grube, M., Brenchley, J.M., Sconochia, G., Fujiwara, H., Price, D., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., Hensel, N., Douek, D.C., and Barret, A.J. (2003) Functional leukemia-associated antigenspecific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102, 2892-2900.
56. Rezvani, K., Brenchley, J.M., Price, D.A., Kilical, Y., Gostick, E., Sewell, A.K., Li, J., Mielke, S., Douek, D.C., and Barrett, A.J. (2005) T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer. Res. 11, 8799-8807.
57. Gillmore, R., Xue, S.A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S.C., Bellantuono, I., Ghani, Y., Coombes, R.C., Waxman, J., and Stauss, H.J. (2006) Detection of Wilms' tumor antigen - specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin. Cancer. Res. 12, 34-42.
58. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, H., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I., and Sugiyama, H. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U. S. A. 101, 13885-13890.
59. Tsuboi, A., Oka, Y., Ogawa, H., Elisseeva, O.A., Li, H., Kawasaki, K., Aozasa, K., Kishimoto, T., Udaka, K., and Sugiyama, H. (2000) Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J. Clin. Immunol. 20, 195-202.
60. Nakajima, H., Kawasaki, K., Oka, Y., Tsuboi, A., Kawakami, M., Ikegame, K., Hoshida, Y., Fujiki, F., Nakano, A., Masuda, T., Wu, F., Taniguchi, Y., Yoshihara, S., Elisseeva, O.A., Oji, Y., Ogawa, H., Azuma, I., Kawase, I., Aozasa, K., and Sugiyama, H. (2004) WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol. Immunother. 53, 617-624.
61. Yamamura, Y., Sakatani, M., Ogura, T., and Azuma, I. (1979) Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer 43, 1314-1319.
62. Ochiai, T., Sato, H., Hayashi, R., Asano, T., Sato, H., and Yamamura, Y. (1983) Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol. Immunother. 14, 167-171.
63. Hayashi, A. and Noda, A. (1996) Does the cell wall skeleton from Bacille Calmette-Guerin directly induce interferongamma, independent of interleukin-12? Jpn. J. Clin. Oncol. 26, 124-127.
64. Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O.A., Masuda, T., Nakano, A., Kawakami, M., Oji, Y., Ikegame, K., Hosen, N., Udaka, K., Yasukawa, M., Ogawa, H., Kawase, I., and Sugiyama, H. (2003) Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78, 56-61.
65. Tsuboi, A., Oka, Y., Osaki T., Kumagai, T., Tachibana, I., Hayashi, S., Murakami, M., Nakajima, H., Elisseeva, O.A., Wu, F., Masuda, T., Yasukawa, M., Oji, Y., Kawakami, M., Hosen, N., Ikegame, K., Yoshihara, S., Udaka, K., Nakatsuka, S., Aozasa, K., Kawase, I., and Sugiyama, H. (2004) WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol. Immunol. 48, 175-184.
66. Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., and Weber, J. (1999) Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5, 2756-2765.
67. Pullarkat, V., Lee, P.P., Scotland, R., Rubio, V., Groshen, S., Gee, C., Lau, R., Snively, J., Sian, S., Woulfe, S.L., Wolfe, R.A., and Weber, J.S. (2003) A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 9, 1301-1312.
68. Nilsson, L., Astrand-Grundstrom, I., Arvidsson, I., Jacobsson, B., Hellstrom-Lindberg, E., Hast, R., and Jacobsen, S.E. (2000) Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012-2021.
69. Mailaender, V., Scheibenbogen, C., Thiel, E., Letsch, A., Blau, I. W., and Keilholz, U. (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18, 165-166.
70. Morita, S., Oka, Y., Tsuboi, A., Kawakami, M., Maruno, M., Izumoto, S., Osaki, T., Taguchi, T., Ueda, T., Myoui, A., Nishida, S., Shirakata, T., Ohno, S., Oji, Y., Aozasa, K., Hatazawa, J., Udaka, K., Yoshikawa, H., Yoshimine, T., Noguchi, S., Kawase, I., Nakatsuka, S., Sugiyama, H., and Sakamoto, J. (2006) A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn. J. Clin. Oncol. 36, 231-236.
71. Drakos, E., Rassidakis, G.Z., Tsioli, P., Lai, R., Jones, D., and Medeiros, L.J. (2005) Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl. Immunohistochem. Mol. Morphol. 13, 132-137.
72. Azuma, T., Otsuki, T., Kuzushima, K., Froelich, C.J., Fujita, S., and Yasukawa, M. (2004) Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin. Cancer Res. 10, 7402-7412.
73. Knights, A.J., Zaniou, A., Rees, R.C., Pawelec, G., and Muller, L. (2002) Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol. Immunother. 51, 271-281.
74. Muller, L., Knights, A., and Pawelec, G. (2003) Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J. 4, 57-66.
75. Kobayashi, H., Nagato, T., Aoki, N., Sato, K., Kimura, S., Tateno, M., and Celis, E. (2006) Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol. Immunother. 55, 850-860.
76. Fujiki, F., Oka, Y., Tsuboi, A., Kawakami, M., Kawakatsu, M., Nakajima, H., Elisseeva, O.A., Harada, Y., Ito, K., Li, Z., Tatsumi, N., Sakaguchi, N., Fujioka, T., Masuda, T., Yasukawa, M., Udaka, K., Kawase, I., Oji, Y., and Sugiyama, H. (2007) Identification and characterization of a WT1 (Wilms tumor hene) protein-derived HLADRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J. Immunother. 30(3), 282-293.
77. Noguchi, M., Itoh, K., Suekane, S., Yao, A., Suetsugu, N., Katagiri, K., Yamada, A., Yamana, H., and Noda, S. (2004) Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci. 95, 77-84.
78. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iiuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S., and Lauria, F. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662.
79. Ercolini, A.M., Ladle, B.H., Manning, E.A., Pfannenstiel, L.W., Armstrong, T.D., Machiels, J.P., Bieler, J.G., Emens, L.A., Reilly, R.T., and Jaffee, E.M. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201, 1591-1602.
80. Chong, G. and Mors, M.A. (2005) Combining cancer vaccines with chemotherapy. Expert Opin. Pharmacother. 6, 2813-2820.
81. Suzuki, K., Kapoor, V., Jassar, A.S., Kaiser, L.R., and Albelda, S.M. (2005) Gemcitabine selectively eliminates slpenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721.
82. Kawakami, M., Oka, Y., Tsuboi, A., Harada, Y., Elisseeva, O.A., Furukawa, Y., Tsukaguchi, M., Shirakata, T., Nishida, S., Nakajima, H., Morita, S., Sakamato, J., Kawase, I., Oji, Y., and Sugiyama, H. (2007) Clinical and immunological responses to the vaccination with very low dose (5. μg/body ) of WT1 peptide in a patient with chronic myelomonocytic leukemia. Int. J. Hematol., in press.
83. Oka, Y., Tsuboi, A., Kawakami, M., Elisseeva, O.A., Nakajima, H., Udaka, K., Kawase, I., and Sugiyama, H. (2006) Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr. Med. Chem. 13, 2345-2352.
84. Hori, A., Kami, M., Kim, S.-W., Murashige, N., Sakiyama, M., Kojima, R., Hamaki, T., Makimoto, A., Miyakoshi, S., Masuo, S., Taniguchi, S., Kunitoh, H., and Takaue, Y. (2004) Urgent need for a validated tumor response evaluation system for use in immunotherapy. Bone Marrow Transplant. 33, 255-256.